Megestrol Acetate Should NOT Be Used for Weight Loss in Geriatric Patients
Megestrol acetate (Megace) should be avoided in elderly patients with weight loss due to lack of efficacy in this population and significant safety concerns, including increased mortality, thromboembolic events, and adrenal suppression. The FDA has only approved megestrol acetate for AIDS-related cachexia, not for geriatric weight loss 1.
Evidence Against Use in Geriatric Populations
Mortality Risk
The most concerning finding is increased all-cause mortality in elderly nursing home residents treated with megestrol acetate. A large case-control study of 709 nursing home residents (mean age 84 years) with significant weight loss found that those treated with megestrol acetate had a median survival of 23.9 months compared to 31.2 months in matched controls (p<0.001) 2. This represents a substantial mortality signal that cannot be ignored.
Lack of Weight Gain Efficacy
Multiple studies demonstrate that megestrol acetate fails to produce meaningful weight gain in geriatric patients:
- A 2022 retrospective study of hospitalized older patients (≥65 years) showed no significant weight gain after 19 days of treatment (0.95 kg increase, not statistically significant) 3
- The same study found albumin actually decreased by 0.4 g/dL 3
- A 2005 randomized trial in recently hospitalized elderly patients (mean age 83) found no significant differences in appetite between treatment groups, though prealbumin increased at higher doses 4
Serious Adverse Effects in the Elderly
Adrenal Suppression: This is particularly problematic and dose-dependent:
- At 400 mg daily: 70% had morning cortisol <8 ng/mL at 20 days
- At 800 mg daily: 78% had suppressed cortisol at 20 days
- Suppression persisted at 63 days in 30-56% of patients 4
Thromboembolic Events: Meta-analyses show increased risk (RR 1.84; 95% CI 1.07-3.18) 5, which is particularly dangerous in elderly patients with limited mobility.
Edema: Increased risk (RR 1.36; 95% CI 1.07-1.72) 5, problematic in elderly patients with heart failure or renal insufficiency.
Cancer Cachexia Context (Not Applicable to General Geriatrics)
The 2020 ASCO guideline addresses megestrol acetate specifically for cancer cachexia, not general geriatric weight loss 5. Even in cancer patients, the guideline notes:
- Weight gain is primarily adipose tissue, not skeletal muscle
- Benefits must be weighed against thromboembolic events, edema, and adrenal suppression
- The evidence is from cancer and AIDS populations, not general elderly patients
The 2003 oncology guideline confirms megestrol acetate increases appetite and weight in cancer patients at minimum doses of 160 mg daily 6, but this cannot be extrapolated to non-cancer elderly patients.
Clinical Algorithm for Geriatric Weight Loss
Instead of megestrol acetate, pursue this approach:
Identify and treat underlying causes:
- Depression (extremely common)
- Medication side effects (polypharmacy)
- Dental problems/dysphagia
- Social isolation/inability to shop or cook
- Undiagnosed malignancy or chronic disease
Optimize mealtime environment:
- One study showed megestrol only worked when combined with optimal feeding assistance 7
- Address feeding assistance needs
- Modify food texture if needed
Consider safer alternatives:
- Nutritional supplementation
- Dietary counseling
- Treatment of specific deficiencies
Reserve pharmacotherapy for specific indications:
Critical Caveat
The FDA label explicitly states megestrol acetate is "known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function" 1. Given that elderly patients frequently have decreased renal function, this further argues against use in this population.
The evidence is clear: megestrol acetate increases mortality without providing meaningful benefit in elderly patients with weight loss. It should not be used in general geriatric practice.